Oric Pharmaceuticals provides early Phase 1b combination data for ORIC-944
ORIC-944 is a potent and selective allosteric inhibitor of the polycomb repressive complex 2 via allosteric targeting of the embryonic ectoderm ...
Taiwan News4 天
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational ...
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...